Galectin Therapeutics Inc.
01/21/2026 | Press release | Distributed by Public on 01/21/2026 16:01
Management Change/Compensation (Form 8-K)
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On January 16, 2026, at the recommendation of the Company's compensation committee, the Company's board of directors approved a $300,000 cash retention bonus for the Company's Chief Medical Officer, Dr. Khurram Jamil, and a $150,000 cash retention bonus for the Company's Chief Financial Officer, Jack Callicutt. The retention bonuses will be paid in 3 equal payments on each of June 1, 2026, September 1, 2026 and December 1, 2026. These retention bonuses are required to be paid back to the Company by the officers if they voluntarily resign without good reason or are terminated for cause, as described in their respective employment agreements, prior to December 31, 2026.
Galectin Therapeutics Inc. published this content on January 21, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 21, 2026 at 22:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]